Next Phase Newsletter

A venture capital firm with USA offices is currently seeking new investments in the healthcare IT and tech enabled healthcare services sectors. The firm has raised 5 healthcare funds over the last 15 years and is currently deploying out of a late-seed stage focused as well as a Series A focused fund. The firm looks to invest in companies at venture and growth stage. The initial investment size typically ranges from $2 -$6 million. 
 
The firm is looking for new investments in the Healthcare IT and tech enabled healthcare services sectors. The firm focuses on healthcare companies targeting software, platform technology, solutions, data, and analytics. The fund is most interested in companies seeking to improve patient care and the provider experience, reduce healthcare costs, or make the healthcare industry more efficient in this rapidly changing marketplace. The firm has been active in HCIT companies developing eSource technology for use in clinical trials, clinical documentation intelligence, EHR system, and online source of research tools for global life science laboratories. 
 
The firm typically invests in private companies that have between $500K-$7M of annual revenue with a proven product and customer base. The firm typically looks to be a lead investor and usually requires a board or board observer seat post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A family office investment firm based in the US. The firm is actively seeking investment opportunities in the medtech space. Typical investment size is $250K, though the firm is capable of investing up to $1M. The firm invests anywhere from Seed to Series C rounds (growth/revenue-generating stage), and prefers to invest in USA-based companies. 
 
Within life sciences, the firm is primarily interested in medical devices. In particular, the firm is interested in surgical devices targeting areas including cancer, orthopedics, renal, cardiovascular, and neuro-related diseases as well as sepsis. The firm is open to companies in the earliest stages though they would like to see a working prototype in place prior to investment. The firm invests in all classes of medical devices including 510k and PMA. 
 
The firm has no specific company or management team requirements. The firm prefers to act as a co-investor. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A single-family evergreen fund headquartered in the US exclusively invests in medical devices; so far there are 15 portfolio companies from the U.S., Europe, and Israel, however the firm is open to investing global companies. The firm has two investment modalities: (1) investing in later-stage, commercial companies with typical check size being around $30M USD and (2) investing in early-stage companies with typical check size being around $10M USD. The earliest the firm will invest in is companies with clinical human data. The firm is active with the companies they invest in and will lead investments. 
 
The firm exclusively invests in medical device companies in a range of diseases states including, but not limited to, oncology, cardiovascular disease, and ophthalmology. The firm also invests in diagnostic devices. The firm is open to all classes of devices. Companies must show at least clinical human data. 
 
The firm will generally seek to take a board seat. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A firm with offices in the US and Japan generally invests in Series A equity rounds, and typically commits a total of $1-4 million over the course of an investment. The firm invests 70% of its capital in the USA and Israel, with the remaining 30% in Japan. Under certain circumstances, the firm will invest outside those regions.  
 
The firm invests in advanced therapeutics, healthcare IT, novel (sensor based IoT) devices and diagnostics, and second generation tools and technologies in the biotech R&D/laboratory innovation field. The firm is open to any indication area, and has a particular interest in diseases that afflict the elderly including Alzheimer’s disease and cancer. DEFTA Partners prefers to invest in technologies at an early stage of development. 
 
The firm is interested in working with high quality management teams. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture capital firm headquartered in London invests in early-stage global health-tech companies from Pre-Seed to Series A rounds with flexible check sizes. RYSE has partnerships with key accelerators, global pharmaceuticals, and government organizations.  
 
The firm invests in digital health, diagnostics, and data applications such as CRMs and databases. The firm does not invest in therapeutics. The firm is generally indication-agnostic but has a preference in oncology. 
 
The firm will act as a lead and co-investor and typically takes board or observer seats. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

An early stage VC founded by a group of alumni from a leading university is based in the US. The group currently has $100M, under management. The group focuses on Angel to Series B stage companies across various sectors, including pharmaceutical, medical device, services and tools, and digital health. The typical investment size is between $1M to $2M. The group also syndicates with other investors for larger investments. The firm looks to make investments across the globe. 
 
The firm is currently looking for new opportunities in the life science space. The fund is opportunistic in terms of sectors, subsectors and indications. The fund typically invests in seed rounds and series A rounds. Historically, the fund has been active in life science companies developing innovative platform technologies and cross-disciplinary technologies. 
 
The firm focuses on investments in private companies and typically invests in pre-clinical and early clinical stage companies with strong and experienced management teams. The firm will take a board seat or observer seat occasionally, depending on the investments. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A Private Equity firm with multiple offices throughout the US is currently making investments out of its latest fund of over $700M. The firm looks to make multi-stage investments ranging from $20-$50 million. The firm is willing to review opportunities from around the Globe with a heavy emphasis on North America. 
 
The firm is currently interested broadly in the healthcare space including Medical Technology, Therapeutics, Diagnostics, Laboratory Equipment, Healthcare IT and R&D services. For medical technology the firm is looking for companies that have at least an alpha prototype and have some efficacy data. For companies working with therapeutics the firm is looking for assets that are in Phase II of clinical trials and will only consider companies in Phase I if they have efficacy data. The firm generally does not look for companies in the cardiovascular space and they are open to orphan indications. The firm is also open to investing in companies that have products already on the market. 
 
The firm looks for a strong management team to be in place and is open to invest in both private and publicly held companies. For companies that are privately held the firm generally looks to take a board seat. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.